CSI Market
Sign In | Register

Reata Pharmaceuticals Inc (RETA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RETA Annual Cash Flow →
This page allows investors to follow Reata Pharmaceuticals Inc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2023)
6 Months 		(Mar 31 2023) (Dec 31 2022) (Sep 30 2022) (Jun 30 2022)
Operating Activities
Income76.88
Depreciation & amortization0.58
Amortization of Other Assets0.05
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-13.28
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation58.42
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Capital Expenditures Incurred But Not Yet Paid0.37
Gain Loss On Termination Of Lease-
Increase Decrease In Payable To Collaborators-
Increase Decrease In Operating Lease Liability0.07
Non Cash Interest Expense On Liability Related To Sale Of Future Royalty17.68
Amortization Of Discount Premium On Marketable Debt Securities-4.63
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-22.66
Increase (Decrease) in Accounts Payable1.01
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities58.85
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-35.05
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-289.65
Discontinued operations0.00
Net Cash flow from Operating Activities-151.38
Investing Activities
Capital Expenditures-0.42
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities372.42
Payments to Acquire Marketable Securities-303.96
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities68.05
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.39
Long-term debt - borrowings72.56
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock17.68
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments On Deferred Offering Costs-
Payments On Deferred Discount And Issuance Costs-
Payments On Deferred Issuance Costs-
Proceeds From Sale Of Future Royalties Net Of Issuance Cost-
Payments On Proceeds From Long Term Debt-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities89.86
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-151.79
Total Cash Flow6.53
4 historic quarters locked

Sign in to unlock the full Reata Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Reata Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-23-039225

Figures are derived from filed reports and may be restated. Historical data is subject to revision.